Skip to content

Talking to your doctor about GLP-1 medications

How to prepare for the appointment and the questions worth asking, so you get a productive conversation.

Updated Sep 26, 2026Evidence-backed

A focused appointment gets you further than a rushed one. A little prep helps you and your clinician make a decision together.

Before the appointment

  • Write down your health history and anything you've already tried.
  • Note your goals and any concerns (cost, side effects, how long you'd take it).
  • Bring your insurance details so coverage can be part of the conversation. Many employer plans don't cover GLP-1s for weight loss at all, and plans that do often add conditions. Our guide on understanding insurance coverage explains what to look up first.

Questions to ask

  • Am I a candidate for a GLP-1 medication given my history? Wegovy and Zepbound are approved for adults with obesity, or with overweight plus at least one weight-related health condition. For what the major US diabetes guideline says about who these medications are recommended for, see what the ADA guidelines say about GLP-1 medications.
  • What are the realistic benefits and risks for me?
  • What monitoring or follow-up would we do?
  • What happens if I stop, and how would we decide that together?
  • If cost is a barrier, are there alternatives or assistance programs?

After the appointment

  • Write down what you decided and any next steps (labs, prior authorization, a follow-up date).
  • If a prior authorization is needed, ask who submits it and roughly how long it takes.

If you're refused a prescription

A "no" isn't always the end of the conversation. Ask what specifically rules it out for you. A clinical reason, such as a history that makes the medication unsafe or not meeting the criteria your clinician uses, is worth understanding, and asking for a second opinion from an obesity-medicine specialist is a normal, reasonable request. If the refusal comes with a lecture instead of a reason, our guide on weight stigma in healthcare settings covers how to recognize a dismissive provider and advocate for yourself.

Once you're on treatment

Other conversations come up later. These guides cover the most common ones:

This is peer information, not medical advice. Your clinician knows your full picture β€” use these prompts to start the conversation, not to replace it.

doctorappointmentsconversations

Was this helpful?

100% of 1 found this helpful

Common questions

Questions people often ask about this topic.

  • How should I prepare before asking my doctor about a GLP-1?

    Write down your health history and anything you've already tried, note your goals and concerns (cost, side effects, how long you'd take it), and bring your insurance details so coverage is part of the conversation instead of a surprise afterward.

  • What questions should I ask my doctor about GLP-1 medications?

    The core ones: whether you're a candidate given your history; the realistic benefits and risks for you specifically; what monitoring or follow-up you'd do; what happens if you stop and how you'd decide that together; and, if cost is a barrier, whether there are alternatives or assistance programs.

  • What should I do after the appointment?

    Write down what you decided and any next steps: labs, prior authorization, a follow-up date. If a prior authorization is needed, ask who submits it and roughly how long it takes so you know when to follow up.

  • What if my doctor says no to a GLP-1 prescription?

    Ask what specifically rules it out for you. A clinical reason is worth understanding, and a second opinion from an obesity-medicine specialist is a normal, reasonable request. If the refusal comes with a lecture instead of a reason, that may be weight stigma, and it's fair to advocate for yourself or seek another provider.

  • Will my insurance cover a GLP-1 if my doctor prescribes one?

    Not automatically. A prescription and coverage run on separate tracks. In KFF's 2025 survey of employers, only 16% of firms with 200 to 999 workers and 43% of firms with 5,000 or more workers covered GLP-1s for weight loss, and about a third of covering firms required a dietitian, case manager, therapist, or lifestyle program. Bringing your insurance details lets your clinician factor coverage into which medication to try, and our insurance coverage guide explains what to check first.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

3Supporting

  • 2025 Employer Health Benefits Survey (external link)

    KFF, 2025 Β· Reporting Β· Moderate evidence

    (2025)

    Released October 22, 2025. Among firms offering health benefits, 16% of firms with 200-999 workers, 30% with 1,000-4,999 and 43% with 5,000+ cover GLP-1 agonists primarily for weight loss; 34% of covering firms require enrollees to meet with a dietitian, case manager or therapist, or join a lifestyle program. Supports the guide's point that a prescription does not guarantee coverage. Re-check when the 2026 survey is released.

  • Wegovy (semaglutide) injection prescribing information (external link)

    FDA label via DailyMed, 2026 Β· Clinical guideline Β· Moderate evidence

    (2026)

    Wegovy label (rev. June 2026): indicated with diet and physical activity for adults with obesity, or overweight with at least one weight-related comorbid condition (plus pediatric and cardiovascular indications). Supports the candidacy prompt.

  • Zepbound (tirzepatide) injection prescribing information (external link)

    FDA label via DailyMed, 2026 Β· Clinical guideline Β· Moderate evidence

    (2026)

    Zepbound label: indicated with diet and physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight with at least one weight-related comorbid condition; also moderate to severe obstructive sleep apnea in adults with obesity. Supports the candidacy prompt.

Revision history

Last updated Β· 4 revisions recorded.

Show what changed
  1. v4

    Evidence sources 0 β†’ 3

  2. v3

    Common questions revised

  3. v2

    Body revised

  4. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related terms

    • Hazard ratio β€” A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
    • Sharps container β€” A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
    • Oral semaglutide β€” Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.

    Related guides

    • Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis β€” GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
    • Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration β€” Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
    • Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo β€” There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.